ASO-Based PKM Splice-Switching Therapy Inhibits Hepatocellular Carcinoma Growth

Researchers explored the potential of antisense oligonucleotides (ASO)-based pyruvate kinase (PKM) splice switching as a targeted therapy for liver cancer. A more potent lead constrained-ethyl/DNA ASO induced PKM splice switching and inhibited the growth of cultured HCC cells.